JNJ-80202135, Placebo subcutaneous without Nipocalimab
80202135SJS3001
Phase 3 small_molecule active
Quick answer
JNJ-80202135, Placebo subcutaneous without Nipocalimab for Sjögren's Disease is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Sjögren's Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active